Biotech · Private company · Palo Alto, CA, US
Amygdala Neurosciences, Inc.
Track this companyFree. Adds Amygdala Neurosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards2
- Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.Fiscal year 2024 · $55KNIH RePORTER 3U43AA030689-01A1S1 · fetched Nov 12, 2026
- Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.Fiscal year 2024 · $1MNIH RePORTER 5U43AA030689-02 · fetched Nov 12, 2026